Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Insmed Incorporated logo

Insmed Incorporated (INSM) Stock Ticker

NASDAQ: INSM · Healthcare · Biotechnology
$117.48-3.06%
USD · as of 2026-09-28 · market cap $25.5B
Open INSM in TickrDownload for iPhone

INSM right now

Growing revenue 154% a year on 83% gross margins.
Options expect by Oct 6±7.8%
Options expect by Oct 29±16.1%
Priced in for Oct 29 earnings±16.1%
IV rank (30-day)45% · fair
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full INSM picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on INSM
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Insmed Incorporated

Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.

INSM stock facts

Ticker symbolINSM
ExchangeNASDAQ Global Select
SectorHealthcare
IndustryBiotechnology
Market cap$25.5B
CEOWilliam H. Lewis
Employees1,664
HeadquartersBridgewater, NJ, US
IPO date2000-06-01
Websitewww.insmed.com

What you can see for INSM on Tickr

Live INSM price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the INSM report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for Insmed Incorporated?

The ticker symbol for Insmed Incorporated is INSM, listed on the NASDAQ Global Select.

What is INSM?

Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its…

HomeExploreMarketLists
All pages